Goldman Sachs raises Taysha Gene Therapies target to $13
Goldman Sachs analyst Salveen Richter maintained a Buy rating on Taysha Gene Therapies and raised the price target to $13 from $11, citing a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Goldman Sachs analyst Salveen Richter has maintained a Buy rating on Taysha Gene Therapies (NASDAQ: TSHA) and increased the price target to $13 from $11. The adjustment reflects a revised outlook on the company's valuation and potential market performance.
The decision to raise the price target comes as the firm evaluates the current positioning of Taysha Gene Therapies within the biotechnology sector. The new target of $13 represents an increase over the previous estimate of $11, signaling confidence in the company's future growth trajectory.
Taysha Gene Therapies focuses on the development of gene therapies for central nervous system diseases. The company's pipeline and clinical progress are key factors influencing analyst ratings and price targets.
The following table outlines the revised rating details:
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $11 |
| New Price Target | $13 |
Investors will monitor upcoming clinical data and regulatory developments that could impact the stock's performance relative to the new price target.
What specific clinical catalysts are expected to drive the stock toward the new $13 price target?
How might the broader biotech sector's performance influence Taysha's ability to sustain this revised valuation?
What regulatory milestones should investors prioritize in the upcoming quarters?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
